Targeting the metabolic vulnerability of drug-resistant B-cell lymphoma with the MPC inhibitor MITO-21

• Forschungsstelle: INNOSUISSE
• Projektnummer: 139.810 INNO-LS
• Projekttitel Englisch: Targeting the metabolic vulnerability of drug-resistant B-cell lymphoma with the MPC inhibitor MITO-21

Schlüsselwörter (Englisch)

Life sciences, Biotechnology and processing

Abstract (Englisch)

MPC Therapeutics SA and the Institute of Oncology Research (IOR) test whether MITO-21, a mitochondrial pyruvate carrier inhibitor, can target drug-resistant B-cell lymphoma and resensitize it to existing treatments ? a new metabolic approach.